189 related articles for article (PubMed ID: 21278302)
1. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
Sorrentino R; Morello S; Forte G; Montinaro A; De Vita G; Luciano A; Palma G; Arra C; Maiolino P; Adcock IM; Pinto A
Am J Respir Crit Care Med; 2011 May; 183(10):1369-79. PubMed ID: 21278302
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma.
Sorrentino R; Morello S; Luciano A; Crother TR; Maiolino P; Bonavita E; Arra C; Adcock IM; Arditi M; Pinto A
J Immunol; 2010 Oct; 185(8):4641-50. PubMed ID: 20855872
[TBL] [Abstract][Full Text] [Related]
3. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
4. Plasmacytoid dendritic cells play a key role in tumor progression in lipopolysaccharide-stimulated lung tumor-bearing mice.
Rega A; Terlizzi M; Luciano A; Forte G; Crother TR; Arra C; Arditi M; Pinto A; Sorrentino R
J Immunol; 2013 Mar; 190(5):2391-402. PubMed ID: 23355734
[TBL] [Abstract][Full Text] [Related]
5. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA.
Suzuki K; Suda T; Naito T; Ide K; Chida K; Nakamura H
Am J Respir Crit Care Med; 2005 Apr; 171(7):707-13. PubMed ID: 15640365
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
7. Regulatory function of CpG-activated B cells in late-phase experimental allergic conjunctivitis.
Miyazaki D; Kuo CH; Tominaga T; Inoue Y; Ono SJ
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1626-35. PubMed ID: 19060266
[TBL] [Abstract][Full Text] [Related]
8. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
Brummel R; Roberts TL; Stacey KJ; Lenert P
Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
Yuan S; Qiao T; Chen W
Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
11. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
13. A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed toll-like receptor-9 on liver NKT cells.
Tsujimoto H; Ono S; Matsumoto A; Kawabata T; Kinoshita M; Majima T; Hiraki S; Seki S; Moldawer LL; Mochizuki H
J Hepatol; 2006 Dec; 45(6):836-43. PubMed ID: 17030073
[TBL] [Abstract][Full Text] [Related]
14. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer.
Forte G; Rega A; Morello S; Luciano A; Arra C; Pinto A; Sorrentino R
J Immunol; 2012 Jun; 188(11):5357-64. PubMed ID: 22516955
[TBL] [Abstract][Full Text] [Related]
15. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
16. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
[TBL] [Abstract][Full Text] [Related]
17. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway.
Xu W; Tamura T; Takatsu K
Int Immunopharmacol; 2008 Feb; 8(2):351-61. PubMed ID: 18182251
[TBL] [Abstract][Full Text] [Related]
18. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
[TBL] [Abstract][Full Text] [Related]
19. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
20. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response.
Núñez NG; Andreani V; Crespo MI; Nocera DA; Breser ML; Morón G; Dejager L; Libert C; Rivero V; Maccioni M
Cancer Res; 2012 Feb; 72(3):592-603. PubMed ID: 22139376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]